PIK3CA mutation–induced immune microenvironment remodeling sensitizes cervical cancer to immunotherapy
Frontiers in Immunology · 25.03.2026 · 17
DOI: 10.3389/fimmu.2026.1780752 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Immunology, online erschienen am 25.03.2026. Verfasst von Fei Zhu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Tumor Microenvironment, Class I Phosphatidylinositol 3-Kinases, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
PIK3CA is one of the most frequently mutated genes in cervical cancer (CC). However, its clinical utility is hampered by paradoxical treatment-dependent outcomes, restricting its application in precision oncology. To address this issue, we constructed a high-resolution single-cell transcriptomic atlas of the CC tumor microenvironment. It was found that PIK3CA mutations induce a dichotomous TME, simultaneously associated with marked T-cell inflammation and resistance to adaptive immune responses. Malignant epithelial subsets induce CD8 + T-cell exhaustion through both canonical PD-L1-PD-1 signaling and the non-canonical SPP1-CD44 axis. Additionally, PIK3CA mutations enrich for MMP9 + macrophages that promote tumor angiogenesis through ANGPTL4 signaling. This dual landscape of T-cell exhaustion and active angiogenesis provides a framework for the observed synergy between PD-1 blockade and anti-angiogenic therapies. The findings demonstrate that the presence of PIK3CA mutations is a key predictive biomarker for guiding combination immunotherapy in CC and identify a rational basis for co-targeting distinct immune and vascular resistance pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
- Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
- Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Zitieren
APA
Zhu, F., Xie, X., Wang, C., Liu, J., Chen, Y., Hu, D., & Xu, Q. (2026). PIK3CA mutation–induced immune microenvironment remodeling sensitizes cervical cancer to immunotherapy. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1780752
Vancouver
Zhu F, Xie X, Wang C, Liu J, Chen Y, Hu D, et al. PIK3CA mutation–induced immune microenvironment remodeling sensitizes cervical cancer to immunotherapy. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1780752
BibTeX
@article{Zhu2026,
author = {Zhu, Fei and Xie, Xingyun and Wang, Cong and Liu, Jin and Chen, Ying and Hu, Dan and Xu, Qin},
title = {PIK3CA mutation–induced immune microenvironment remodeling sensitizes cervical cancer to immunotherapy},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1780752}
}
EUVIMED